IL-MI-JACK
1.6.2022 17:12:06 CEST | Business Wire | Press release
Mi-Jack Products, the industry leader in Rubber Tired Gantry (RTG) Cranes, container handling machinery, and technology for port and intermodal facilities, has announced a successful acquisition of Yardeye GmbH, a Germany-based automation, collision avoidance, and work zone protection provider for the port and rail container industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005458/en/
Yardeye’s RFID and GNSS-based equipment, personnel Real Time Locating System (RTLS), and Collision Avoidance System (CAS) fit seamlessly into Mi-Jack's Mi-Star® technology platform, which provides everything from differential GPS automated steering and GPS inventory management to virtualized operations view and centralized fleet management.
Combining both companies’ skilled and experienced technology groups into one will facilitate continued innovation and excellence for automation, collision avoidance, and work zone protection within ports and intermodal terminals.
Aaron Newton, VP of Sales for Mi-Jack, said, “By bringing these two similar but unique technology platforms together, the port and intermodal industries will now have an end-to-end automation solution with superior redundancy, led by a company [Mi-Jack] that’s been rooted in the container handling business for over 65 years.”
According to Simon Fiera, VP of Technology at Mi-Jack, “We see Yardeye as a key component of integrating into an agnostic crane manufacturing base for the purposes of automation and work zone protection. We look forward to the innovations and efficiencies that will come from combining the skillsets and experiences of both the European and North American technology teams.”
With this expanded footprint, Mi-Jack brings its world class support and service to Yardeye customers in North America and will provide Mi-Star technology solutions to ports and terminals across Europe. Mi-Jack provides 24/7/365 service and parts support and has a vast network of highly trained technicians and solutions experts that service customers both in-person and virtually.
Stephan Trauth, Managing Director of Yardeye, said, “We are very proud to join the Mi-Jack group. The know-how of both companies will generate more advanced capabilities and synergies. Together, we will provide an automation portfolio that sets new standards in the rail container industry. The network from Mi-Jack in the North American market and especially their competence will add more value and innovative ideas for our customers. We look forward to this new chapter!”
Christian Augustin, Founder of Yardeye and managing director of indurad said, “The team has been growing Yardeye since 2017 from a concept to a company with a global impact serving the intermodal and container handling industry. We are very proud with what we have achieved, and we believe that together with Mi-Jack, Yardeye will continue its success story, for our customers as well as our employees. indurad and I will continue to focus our activities on radar technology for bulk material handling.”
About Mi-Jack
Mi-Jack is recognized worldwide as an industry leader and innovator in rubber-tired gantry (RTG) cranes and other products and solutions globally. Mi-Jack's Mi-Star suite of automation technology includes AccuSteer , AccuStack , AccuView , VehicleView , and AccuFleet . Mi-Star is installed on thousands of pieces of equipment throughout the world.
Corporate headquarters are in Hazel Crest, Illinois at an ISO 9001:2017 certified facility that produces Translift™ and Travelift® RTG’s now in use on six continents. The company maintains four regional operations headquarters and five sales offices. Mi-Jack is part of the Lanco Group of Companies . For more information, go to www.mi-jack.com .
About Yardeye
Yardeye GmbH (www.yardeye.com ) operates internationally with a focus on port automation and work zone protection in container terminals. By Yardeye’s unique GNSS, RFID, and collisional avoidance technology, terminals are able to identify and track cranes, vehicles, and personnel for efficient intermodal yard operations and work zone protection.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005458/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom